DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. is a phase 2/3, interventional study registered as NCT07440290 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2026-04-01 and due to reach its primary completion in 2029-10. Interventions recorded: Dabrafenib; Trametinib. Conditions listed: Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Gastrointestinal Cancer; Non-Melanoma Skin Cancer (NMSC); Langerhans Cell Histiocytosis (LCH); Cancer; Erdheim-Chester Disease; Thyroid Carcinoma, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small Cell-Lung; Glioma; Multiple Myeloma; Thyroid Carcinoma, Anaplastic; Solid Tumour; Pancreatic Diseases. Primary outcome: Objective response (OR); Durable Clinical Benefit (DCB). Sites: United Kingdom. United Kingdom sites listed: 27. No results are recorded here; the registry entry is the source.